BAC
Bank of America Corporation
BAC has the edge over CARE overall, supported by stronger modeled upside and lower modeled downside.
CARE
Carter Bankshares, Inc.
CARE offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CARE's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CARE.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
CARE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.9x | $29.10 | — |
| Cheap | 6.8x | $39.97 | +37% |
| Fair | 12x | $69.41 | +139% |
| Forward | 12x | $29.10 | — |
| Expensive | 21x | $122 | +318% |
Historical ranges are pointers, not guarantees.
CARE has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CARE on the outlook, with more favorable valuation and earnings expectations.
CARE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect CARE's earnings and revenue to decline, with profitability weakening.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
CARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | -60% |
| Q3 2026 | $5.92 | +335% |
| Q2 2026 | $5.81 | +327% |
| Q1 2026 | $4.87 | +306% |
| Q4 2025 | $1.38 | +30% |
| Q3 2025 | $1.36 | +116% |
| Q2 2025 | $1.36 | +147% |
| Q1 2025 | $1.20 | +107% |
| Q4 2024 | $1.06 | +6% |
CARE has the edge over BAC on earnings, with stronger typical year-over-year growth.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CARE on profitability, with a higher operating margin.
CARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $46.2M | +18% |
| Q2 2026 | $68.7M | +84% |
| Q1 2026 | $106.9M | +189% |
| Q4 2025 | $39.8M | +15% |
| Q3 2025 | $39.1M | +14% |
| Q2 2025 | $37.3M | +11% |
| Q1 2025 | $37M | +11% |
| Q4 2024 | $34.5M | +13% |
CARE has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -4.5 points |
| Q2 2026 | 54% | +26 points |
| Q1 2026 | 103% | +73 points |
| Q4 2025 | 28% | -3.1 points |
| Q3 2025 | 18% | -2.2 points |
| Q2 2025 | 29% | +11 points |
| Q1 2025 | 30% | +8.4 points |
| Q4 2024 | 31% | +37 points |
CARE's operating margin was 14% last quarter, down 4.5 points from the same quarter a year ago, near the bottom of its range since 2021.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
CARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5K | -100% |
| Q2 2026 | -$262.9M | -3522% |
| Q1 2026 | $302.4M | +6131% |
| Q4 2025 | $9M | +8.2% |
| Q3 2025 | $10.3M | +22% |
| Q2 2025 | $7.7M | +$12M |
| Q1 2025 | $4.9M | -70% |
| Q4 2024 | $8.3M | +37% |
CARE has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -37.2K shares |
| 1 year | -2.2% | -493K shares |
| 3 years | -5% | -1.1M shares |
| 5 years | -17% | -4.5M shares |
CARE has 22M diluted shares, down 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2M |
| Q4 2025 | $6M |
| Q3 2025 | $4.9M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CARE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
CARE has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 7.8 | Oversold |
CARE's weekly RSI is 48 (neutral) and its Stochastic is 8 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
CARE PE vs Financial Services Sector
| Metric | CARE | Sector median | Relative |
|---|---|---|---|
| PE | 4.9x | 13x | 62% below |
| PE % | 0 | 63 | 63 pts below |
CARE has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.9 | 2.5% below |
| 20 week MA | $31.4 | 7.4% below |
| 50 week MA | $26.6 | 9.3% above |
| 100 week MA | $22.0 | 32% above |
| 200 week MA | $18.4 | 59% above |
CARE has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.3 | $10.8 | -54% |
| 2021 | $10.8 | $14.9 | +39% |
| 2022 | $14.9 | $16.7 | +12% |
| 2023 | $16.7 | $15.0 | -11% |
| 2024 | $15.0 | $17.6 | +18% |
| 2025 | $17.6 | $19.9 | +13% |
| 2026 YTD | $19.9 | $29.1 | +46% |
CARE has the edge over BAC on returns for 2026, with the stronger performance.